Native platelet ligands and receptors

Native platelet ligands and receptors comprise a diverse group of cell surface proteins and their corresponding binding partners that mediate the critical processes of platelet adhesion, activation, and aggregation [1, 2]. This system includes adhesion receptors like the Glycoprotein Ib-IX-V complex and Glycoprotein VI (GPVI), which bind to von Willebrand factor and collagen, respectively, to tether platelets to the damaged vessel wall [3, 4]. Activation is further mediated by G protein-coupled receptors such as P2Y12 and Protease-activated receptor 1 (PAR1), which respond to soluble agonists like ADP and thrombin [1, 5]. The final common pathway of platelet aggregation is mediated by the integrin alpha-IIb/beta-3 (GP IIb/IIIa) receptor, which binds fibrinogen to form bridges between adjacent platelets [2, 4]. Pharmacological targeting of these receptors and ligands is a cornerstone of cardiovascular medicine, used to prevent arterial thrombosis in patients with coronary artery disease or stroke [3]. However, because these interactions are also essential for normal hemostasis, the primary safety concern for drugs targeting this system is an increased risk of bleeding [5].

Other names

Platelet surface receptorsPlatelet adhesion receptorsPlatelet activation receptorsPlatelet glycoproteinsPlatelet-ligand system

Inhibition of platelet activation and aggregation by blocking specific receptors (e.g., P2Y12, GP IIb/IIIa, PAR1) or inhibiting the synthesis and action of ligands (e.g., Thromboxane A2, von Willebrand factor).